ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study (NCT04707235)
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
🩺 Plain-English Summary (8th-Grade Level)
As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed. ESCORT-HU Extension study aims at evaluating the long-term safety of Siklos® focusing on some questions regarding its safety when used in current practice in adults and paediatric patients treated with Siklos® and followed for up to 5 years. The study will focus on the following concerns : occurrence and incidence of malignancies, leg ulcers, male fertility impairment and serious unexpected AEs causally related to Siklos®.
Who can join: Review the eligibility criteria below.
Location: Amiens - Picardie Hospital Adults — Amiens
Age range: 2 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (87 Sites)
Showing the first 25 of 87 sites.
- Amiens - Picardie Hospital Adults — Amiens,
- Amiens Picardie Hospital Children — Amiens,
- Clinique de l'Europe Amiens — Amiens,
- Angers Hospital Adults — Angers,
- Angers Hospital Center Children — Angers,
- Robert Ballanger Hospital Adults — Aulnay-sous-Bois,
- Robert Ballanger Hospital Children — Aulnay-sous-Bois,
- Avicenne Hospital Adults — Bobigny,
- Jean Verdier Hospital Children — Bondy,
- Bordeaux Hospital Adults — Bordeaux,
- Bordeaux Hospital Children — Bordeaux,
- Ambroise Paré Hospital Children — Boulogne-Billancourt,
- Tours Regional University Hospital Center Adults — Chambray-lès-Tours,
- Estaing Hospital Children — Clermont-Ferrand,
- Louis Mourier Hospital Adults — Colombes,
- Louis Mourier Hospital Children — Colombes,
- Sud Francilien Hospital Center Adults — Corbeil-Essonnes,
- Centre Hospitalier Sud Francilien — Corbeil-Essonnes,
- Sud Oise Public Hospital Group Adults — Creil,
- Henri Mondor Hospital Adults — Créteil,
- Intercommunal Hospital Center of Créteil Adults and Children — Créteil,
- Dreux Hospital Center Children — Dreux,
- Gonesse Hospital Children — Gonesse,
- Marne-La-Vallée Hospital Center Children — Jossigny,
- Grenoble Hospital Adults — La Tronche,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Sickle Cell Disease
- Kidney Function in Sickle Cell Anemia — Chapel Hill, North Carolina
- BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease — Birmingham, Alabama
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease — Bethesda, Maryland
- Acupressure in Patients With Sickle Cell Disease — Irvine, California
- Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) — Chicago, Illinois
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) — Charlotte, North Carolina
Explore by condition: All Sickle Cell Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.